{"id":"https://openalex.org/W2533305249","doi":"https://doi.org/10.1002/cpt.539","title":"Physiologically based pharmacokinetic modeling in regulatory decision\u2010making at the European Medicines Agency","display_name":"Physiologically based pharmacokinetic modeling in regulatory decision\u2010making at the European Medicines Agency","alternate_titles":[],"publication_year":2016,"publication_date":"2016-12-26","ids":{"openalex":"https://openalex.org/W2533305249","doi":"https://doi.org/10.1002/cpt.539","mag":"2533305249","pmid":"https://pubmed.ncbi.nlm.nih.gov/27770430"},"language":"en","primary_location":{"id":"doi:10.1002/cpt.539","doi":"https://doi.org/10.1002/cpt.539","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpt.539","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2533305249"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089087688","display_name":"Elisa Luzon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297934274","display_name":"European Medicines Agency","ror":"https://ror.org/01z0wsw92","country_code":"NL","type":"government","lineage":["https://openalex.org/I1297934274","https://openalex.org/I1320481043"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E Luzon","raw_affiliation_strings":["European Medicines Agency (EMA) London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"European Medicines Agency (EMA) London UK","institution_ids":["https://openalex.org/I1297934274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004817670","display_name":"Kevin V. Blake","orcid":"https://orcid.org/0000-0001-7165-4579","observed_orcids":["https://orcid.org/0000-0001-7165-4579"]},"institutions":[{"id":"https://openalex.org/I1297934274","display_name":"European Medicines Agency","ror":"https://ror.org/01z0wsw92","country_code":"NL","type":"government","lineage":["https://openalex.org/I1297934274","https://openalex.org/I1320481043"]}],"countries":["NL"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"K Blake","raw_affiliation_strings":["European Medicines Agency (EMA) London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"European Medicines Agency (EMA) London UK","institution_ids":["https://openalex.org/I1297934274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068622970","display_name":"Susan M. Cole","orcid":"https://orcid.org/0000-0002-4582-6231","observed_orcids":["https://orcid.org/0000-0002-4582-6231"]},"institutions":[{"id":"https://openalex.org/I4405282191","display_name":"Medicines and Healthcare products Regulatory Agency","ror":"https://ror.org/05fan1e59","country_code":"GB","type":"government","lineage":["https://openalex.org/I4405282191"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S Cole","raw_affiliation_strings":["Medicines and Healthcare products Regulatory Agency (MHRA) London UK","Modelling and Simulation Working Group (MSWG), EMA London UK","Pharmacokinetics Working Party (PKWP), EMA London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicines and Healthcare products Regulatory Agency (MHRA) London UK","institution_ids":["https://openalex.org/I4405282191"]},{"raw_affiliation_string":"Modelling and Simulation Working Group (MSWG), EMA London UK","institution_ids":[]},{"raw_affiliation_string":"Pharmacokinetics Working Party (PKWP), EMA London UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089307442","display_name":"Anna Nordmark","orcid":"https://orcid.org/0000-0002-2628-6292","observed_orcids":["https://orcid.org/0000-0002-2628-6292"]},"institutions":[{"id":"https://openalex.org/I1319126558","display_name":"Medical Products Agency","ror":"https://ror.org/0356c4a29","country_code":"SE","type":"government","lineage":["https://openalex.org/I1319126558"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A Nordmark","raw_affiliation_strings":["Medical Products Agency (MPA) Uppsala Sweden","Modelling and Simulation Working Group (MSWG), EMA London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Products Agency (MPA) Uppsala Sweden","institution_ids":["https://openalex.org/I1319126558"]},{"raw_affiliation_string":"Modelling and Simulation Working Group (MSWG), EMA London UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108456434","display_name":"Carolien H.M. Versantvoort","orcid":"https://orcid.org/0009-0001-6030-4271","observed_orcids":["https://orcid.org/0009-0001-6030-4271"]},"institutions":[{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C Versantvoort","raw_affiliation_strings":["Medicines Evaluation Board (MEB), Utrecht, Netherlands","Pharmacokinetics Working Party (PKWP), EMA London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicines Evaluation Board (MEB), Utrecht, Netherlands","institution_ids":["https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Pharmacokinetics Working Party (PKWP), EMA London UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064287394","display_name":"Eva Gil Berglund","orcid":"https://orcid.org/0009-0005-6255-883X","observed_orcids":["https://orcid.org/0009-0005-6255-883X"]},"institutions":[{"id":"https://openalex.org/I1319126558","display_name":"Medical Products Agency","ror":"https://ror.org/0356c4a29","country_code":"SE","type":"government","lineage":["https://openalex.org/I1319126558"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E Gil Berglund","raw_affiliation_strings":["Medical Products Agency (MPA) Uppsala Sweden","Pharmacokinetics Working Party (PKWP), EMA London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Products Agency (MPA) Uppsala Sweden","institution_ids":["https://openalex.org/I1319126558"]},{"raw_affiliation_string":"Pharmacokinetics Working Party (PKWP), EMA London UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5004817670"],"corresponding_institution_ids":["https://openalex.org/I1297934274"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":8.4669,"has_fulltext":false,"cited_by_count":145,"citation_normalized_percentile":{"value":0.98221238,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"102","issue":"1","first_page":"98","last_page":"105"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.9731000065803528,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.9731000065803528,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.017899999395012856,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/physiologically-based-pharmacokinetic-model","display_name":"physiologically based pharmacokinetic modeling","score":0.996999979019165},{"id":"https://openalex.org/keywords/regulatory-decision-making","display_name":"regulatory decision-making","score":0.847000002861023},{"id":"https://openalex.org/keywords/european-medicines-agency","display_name":"European Medicines Agency","score":0.9900000095367432},{"id":"https://openalex.org/keywords/regulatory-guidance","display_name":"regulatory guidelines","score":0.6449999809265137},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.7519999742507935},{"id":"https://openalex.org/keywords/pharmacokinetic-simulation","display_name":"pharmacokinetic simulation","score":0.746999979019165},{"id":"https://openalex.org/keywords/product-labeling","display_name":"product labeling","score":0.7419999837875366}],"concepts":[{"id":"https://openalex.org/C185867374","wikidata":"https://www.wikidata.org/wiki/Q2562769","display_name":"Physiologically based pharmacokinetic modelling","level":3,"score":0.925788938999176},{"id":"https://openalex.org/C3019398576","wikidata":"https://www.wikidata.org/wiki/Q1639780","display_name":"Regulatory agency","level":2,"score":0.7060792446136475},{"id":"https://openalex.org/C2778917124","wikidata":"https://www.wikidata.org/wiki/Q7309705","display_name":"Regulatory science","level":2,"score":0.6819772720336914},{"id":"https://openalex.org/C108170787","wikidata":"https://www.wikidata.org/wiki/Q3951828","display_name":"Agency (philosophy)","level":2,"score":0.6282312273979187},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.4898514449596405},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4857957363128662},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.4508483409881592},{"id":"https://openalex.org/C98045186","wikidata":"https://www.wikidata.org/wiki/Q205663","display_name":"Process (computing)","level":2,"score":0.42616862058639526},{"id":"https://openalex.org/C539667460","wikidata":"https://www.wikidata.org/wiki/Q2414942","display_name":"Management science","level":1,"score":0.4171750247478485},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.40311312675476074},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39846542477607727},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.3813750445842743},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3168795704841614},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.160593181848526},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.15685471892356873},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0},{"id":"https://openalex.org/C3116431","wikidata":"https://www.wikidata.org/wiki/Q31728","display_name":"Public administration","level":1,"score":0.0},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000076722","descriptor_name":"Drug Development","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D000076722","descriptor_name":"Drug Development","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D004335","descriptor_name":"Drug and Narcotic Control","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D004335","descriptor_name":"Drug and Narcotic Control","qualifier_ui":"Q000458","qualifier_name":"organization & administration","is_major_topic":true},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006077","descriptor_name":"Government Agencies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010599","descriptor_name":"Pharmacokinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010829","descriptor_name":"Physiological Phenomena","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011050","descriptor_name":"Policy Making","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020380","descriptor_name":"Needs Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpt.539","doi":"https://doi.org/10.1002/cpt.539","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpt.539","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:27770430","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27770430","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8048999905586243}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W1501922076","https://openalex.org/W1550666041","https://openalex.org/W1979930569","https://openalex.org/W1984755508","https://openalex.org/W2040233060","https://openalex.org/W2059056324","https://openalex.org/W2562558875"],"related_works":["https://openalex.org/W4406041730","https://openalex.org/W4393240814","https://openalex.org/W1482984111","https://openalex.org/W2040233060","https://openalex.org/W7167336504","https://openalex.org/W2783299760","https://openalex.org/W2578326055","https://openalex.org/W3084129423","https://openalex.org/W3185714367","https://openalex.org/W3098681737"],"abstract_inverted_index":{"Physiologically":[0],"based":[1],"pharmacokinetic":[2],"(PBPK)":[3],"modeling":[4,47,87],"is":[5,80,107,144],"a":[6,25,28,32,111],"valuable":[7],"tool":[8],"in":[9,31,48,69,88,110,128,140],"drug":[10],"development":[11,147],"and":[12,36,43,109],"regulatory":[13,50,89,138],"assessment,":[14],"as":[15],"it":[16],"offers":[17],"the":[18,22,41,54,60,74,83,101,115,121,129,135,149],"opportunity":[19],"to":[20,53,73,85,126],"simulate":[21],"pharmacokinetics":[23],"of":[24,34,45,62,76,100,103,113,117],"compound,":[26],"with":[27,65],"mechanistic":[29],"understanding,":[30],"variety":[33],"populations":[35],"situations.":[37],"This":[38],"work":[39],"reviews":[40],"use":[42],"impact":[44,120],"such":[46],"selected":[49],"procedures":[51],"submitted":[52,106],"European":[55],"Medicines":[56],"Agency":[57],"(EMA)":[58],"before":[59],"end":[61],"2015,":[63],"together":[64],"its":[66,93],"subsequent":[67],"reflection":[68],"public":[70,90],"documents":[71,91],"relating":[72],"assessment":[75],"these":[77,118],"procedures.":[78],"It":[79],"apparent":[81],"that":[82],"reference":[84],"PBPK":[86,104],"underrepresents":[92],"use.":[94],"A":[95],"positive":[96],"trend":[97],"over":[98],"time":[99],"number":[102,112],"models":[105],"shown,":[108],"cases":[114],"results":[116,133],"may":[119],"decision-making":[122],"process":[123],"or":[124],"lead":[125],"recommendations":[127],"product":[130],"labeling.":[131],"These":[132],"confirm":[134],"need":[136],"for":[137],"guidance":[139],"this":[141],"field,":[142],"which":[143],"currently":[145],"under":[146],"by":[148],"EMA.":[150]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2533305249","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":23},{"year":2024,"cited_by_count":16},{"year":2023,"cited_by_count":17},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":27},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-10-28T00:00:00"}
